Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/178866
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMozas, Pablo-
dc.contributor.authorNadeu, Ferran-
dc.contributor.authorRivas Delgado, Alfredo-
dc.contributor.authorRivero, Andrea-
dc.contributor.authorGarrote, Marta-
dc.contributor.authorBalagué Ponz, Olga-
dc.contributor.authorGonzález Farré, Blanca-
dc.contributor.authorVeloza, Luis-
dc.contributor.authorBaumann, Tycho-
dc.contributor.authorGiné Soca, Eva-
dc.contributor.authorDelgado, Julio (Delgado González)-
dc.contributor.authorVillamor i Casas, Neus-
dc.contributor.authorCampo Güerri, Elias-
dc.contributor.authorMagnano, Laura-
dc.contributor.authorLópez Guillermo, Armando-
dc.date.accessioned2021-07-06T15:01:37Z-
dc.date.available2021-07-06T15:01:37Z-
dc.date.issued2020-03-05-
dc.identifier.issn2044-5385-
dc.identifier.urihttp://hdl.handle.net/2445/178866-
dc.description.abstractAlthough the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patients, histological transformation (HT) and early relapse still confer a poor prognosis. We sought to describe the patterns of change in treatment, response, and outcome of FL patients at our institution over the last four decades. Seven hundred and twenty-seven patients (389 F/338 M; median age, 57 years) consecutively diagnosed with grade 1-3a FL between 1980 and 2017, categorized into four decades according to the time of diagnosis, constituted the study population. Clinical characteristics, treatment, response, absolute and relative survival, HT, second malignancies (SM), and causes of death were assessed. Median OS for the entire cohort was 17.6 years. From decade 1 to 4, there was an increase in the complete response rate (48 to 70%), progression-free survival (40 to 56% at 5 years), OS (77 to 86% at 5 years), and relative survival ratio (0.83 to 0.94 at 5 years), with no significant differences in the risk of HT or SM. Lymphoma remained the most common cause of death in all four decades. These findings illustrate the overall improvement in outcome for FL patients, but support the need for further research into risk stratification and management.-
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Nature-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41408-020-0299-0-
dc.relation.ispartofBlood Cancer Journal, 2020, vol. 10, num. 31-
dc.relation.urihttps://doi.org/10.1038/s41408-020-0299-0-
dc.rightscc-by (c) Mozas, Pablo et al., 2020-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.classificationImmunoteràpia-
dc.subject.classificationLimfomes-
dc.subject.otherImmunotheraphy-
dc.subject.otherLymphomas-
dc.titlePatterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience.-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec701537-
dc.date.updated2021-07-06T15:01:37Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32139690-
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
701537.pdf822.53 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons